Spironolactone attenuates oxidative stress in patients with chronic kidney disease

Hypertension. 2008 Nov;52(5):e132-3; author reply e134. doi: 10.1161/HYPERTENSIONAHA.108.120568. Epub 2008 Sep 29.
No abstract available

Publication types

  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Adult
  • Angiotensin II Type 1 Receptor Blockers / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Antioxidants / pharmacology*
  • Benzimidazoles / therapeutic use
  • Benzoates / therapeutic use
  • Chronic Disease
  • Cilazapril / therapeutic use
  • Creatinine / urine
  • Cross-Over Studies
  • Dinoprost / analogs & derivatives
  • Dinoprost / urine
  • Diuretics / therapeutic use
  • Female
  • Humans
  • Hydrochlorothiazide / therapeutic use
  • Kidney Diseases / drug therapy
  • Kidney Diseases / physiopathology*
  • Kidney Diseases / urine
  • Male
  • Mineralocorticoid Receptor Antagonists / pharmacology*
  • Oxidative Stress / drug effects*
  • Oxidative Stress / physiology
  • Spironolactone / pharmacology*
  • Telmisartan

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors
  • Antioxidants
  • Benzimidazoles
  • Benzoates
  • Diuretics
  • Mineralocorticoid Receptor Antagonists
  • Hydrochlorothiazide
  • Cilazapril
  • 8-epi-prostaglandin F2alpha
  • Spironolactone
  • Creatinine
  • Dinoprost
  • Telmisartan